Bausch Health R&D spend
Bausch Health Companies Inc. · BHC (TSX) · Laval, QC · Pharmaceuticals
Latest R&D (CAD)
$879.2M
Period ended 2025-12-31
Revenue (CAD)
$14.35B
6.1% of revenue · scale $3.55B
R&D by fiscal period
2025
$879.2M
2024
$843.8M
2023
$815.2M
2022
$688.4M
2021
$582.9M
2020
$606.4M
2019
$625.0M
2018
$535.1M
| Period end | R&D (CAD) | Revenue (CAD) | Native R&D | Form | Source |
|---|---|---|---|---|---|
| 2025-12-31 | $879,216,200 | $14,349,814,800 | $629,000,000 USD | 10-K | SEC EDGAR |
| 2024-12-31 | $843,796,800 | $13,184,325,000 | $616,000,000 USD | 10-K | SEC EDGAR |
| 2023-12-31 | $815,218,800 | $11,819,322,900 | $604,000,000 USD | 10-K | SEC EDGAR |
| 2022-12-31 | $688,387,700 | $10,571,761,200 | $529,000,000 USD | 10-K | SEC EDGAR |
| 2021-12-31 | $582,877,500 | $10,572,019,000 | $465,000,000 USD | 10-K | SEC EDGAR |
| 2020-12-31 | $606,358,000 | $10,768,220,500 | $452,000,000 USD | 10-K | SEC EDGAR |
| 2019-12-31 | $624,969,900 | $11,412,666,900 | $471,000,000 USD | 10-K | SEC EDGAR |
| 2018-12-31 | $535,124,100 | $10,857,966,000 | $413,000,000 USD | 10-K | SEC EDGAR |